188 Chapter 8 154. Hamed, K.; Engelhardt, M.; Jones, M.E.; Saulay, M.; Holland, T.L.; Seifert, H.; Jr, V.G.F. Ceftobiprole versus daptomycin in Staphylococcus aureus bacteremia: A novel protocol for a double-blind, Phase III trial. Futur. Microbiol. 2020, 15, 35–48. 155. Boucher, H.W.; Wilcox, M.; Talbot, G.H.; Puttagunta, S.; Das, A.F.; Dunne, M.W. Once-Weekly Dalbavancin versus Daily Conventional Therapy for Skin Infection. N. Engl. J. Med. 2014, 370, 2169–2179. 156. Cooper, M.M.; Preslaski, C.R.; Shihadeh, K.C.; Hawkins, K.L.; Jenkins, T.C. Multiple-Dose Dalbavancin Regimens as the Predominant Treatment of Deep-Seated or Endovascular Infections: A Scoping Review. Open Forum Infect. Dis. 2021, 8, ofab486. 157. Turner, N.A.; Zaharoff, S.; King, H.; Evans, S.; Hamasaki, T.; Lodise, T.; Ghazaryan, V.; Beresnev, T.; Riccobene, T.; Patel, R.; et al. Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): Study protocol for a phase 2b, multicenter, randomized, openlabel clinical trial. Trials 2022, 23, 1–15. 158. Fowler, V.G., Jr.; Das, A.F.; Lipka-Diamond, J.; Schuch, R.; Pomerantz, R.; Jáuregui-Peredo, L.; Bressler, A.; Evans, D.; Moran, G.J.; Rupp, M.E.; et al. Exebacase for patients with Staphylococcus aureus bloodstream infection and endocarditis. J. Clin. Investig. 2020, 130, 3750–3760. 159. Clinicaltrials.gov. Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase (DISRUPT). Available online: https://clinicaltrials.gov/ct2/show/NCT04160468 (accessed on 15 January 2023). 160. Wire, M.B.; Jun, S.Y.; Jang, I.-J.; Lee, S.-H.; Hwang, J.G.; Huang, D.B. A Phase 1 Study To Evaluate Safety and Pharmacokinetics following Administration of Single and Multiple Doses of the Antistaphylococcal Lysin LSVT-1701 in Healthy Adult Subjects. Antimicrob. Agents Chemother. 2022, 66, e01842-21. 161. Petrovic Fabijan, A.; Lin, R.C.Y.; Ho, J.; Maddocks, S.; Ben Zakour, N.L.; Iredell, J.R. Safety of bacteriophage therapy in severe Staphylococcus aureus infection. Nat. Microbiol. 2020, 5, 465–472. 162. Clinicaltrials.gov. Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects with S. aureus Bacteremia (diSArm). Available online: https:// clinicaltrials.gov/ct2/show/NCT05184764 (accessed on 15 January 2023).
RkJQdWJsaXNoZXIy MTk4NDMw